Effect of ombitasvir/paritaprevir/ritonavir  + dasabuvir regimen on health‐related quality of life for patients with hepatitis C

ConclusionsDuring the active treatment period, small but statistically significant decrements in health‐related quality of life outcomes were observed potentially driven by ribavirin, which were not sustained during the post‐treatment follow‐up period. Differences were observed by patient subgenotype, where health‐related quality of life improvements were consistently higher for genotype 1b patients as compared to genotype 1a patients.

Source: Liver International - February 12, 2018 Category: Gastroenterology Authors: Sammy Saab, Darshan Mehta, Stacie Hudgens, Nathan Grunow, Yanjun Bao, Brett Pinsky Tags: ORIGINAL ARTICLE Source Type: research